Shin DY, Park S, Jang E, Kong JH, et al. Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trials. Leuk Res 2024;143:107542.
PMID: 38924942